10 assets in Vulvar Carcinoma

Therapeutic assets addressing Vulvar Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Vulvar Carcinoma	HRYZ Biotech Co.	P2	B (60)
Cilostazol Vulvar Carcinoma	Emory University	P2	CCC (53)
Ipilimumab Vulvar Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Vulvar Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Vulvar Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Dehydroepiandrosterone Vulvar Carcinoma	Ohio State University Comprehensive Cancer Center	P2	CCC (52)
Fludarabine Vulvar Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Hryz-T101 Vulvar Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Hryz-T101 Tcr-T Cell Vulvar Carcinoma	HRYZ Biotech Co.	P1	CC (43)
[177lu]lu-akir001 Vulvar Carcinoma	Karolinska University Hospital	Early P1	C (39)